Get started
ALTIMMUNE INC COM USD0.0001ALTIMMUNE INC COM USD0.0001ALTIMMUNE INC COM USD0.0001

ALTIMMUNE INC COM USD0.0001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0A4C chart


Full chart

0A4C upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪545.82 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.619 USD
Net income (FY)
‪−88.45 M‬ USD
Revenue (FY)
‪426.00 K‬ USD
Shares float
‪70.48 M‬
Beta (1Y)
3.00

Employees


Employees (FY)
59
Change (1Y)
+7 +13.46%
Revenue / Employee (1Y)
‪7.22 K‬ USD
Net income / Employee (1Y)
‪−1.50 M‬ USD

About Altimmune, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Vipin K. Garg
Website
altimmune.com
Headquarters
Gaithersburg
Founded
1997
FIGI
BBG00X940WQ0
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0A4C news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0A4C is 7.499 USD — it has decreased by −2.30% in the past 24 hours. Watch ALTIMMUNE INC COM USD0.0001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ALTIMMUNE INC COM USD0.0001 stocks are traded under the ticker 0A4C.
0A4C stock has risen by 6.38% compared to the previous week, the month change is a 19.79% rise, over the last year ALTIMMUNE INC COM USD0.0001 has showed a 185.05% increase.
We've gathered analysts' opinions on ALTIMMUNE INC COM USD0.0001 future price: according to them, 0A4C price has a max estimate of 28.00 USD and a min estimate of 10.00 USD. Watch 0A4C chart and read a more detailed ALTIMMUNE INC COM USD0.0001 stock forecast: see what analysts think of ALTIMMUNE INC COM USD0.0001 and suggest that you do with its stocks.
0A4C reached its all-time high on Feb 18, 2021 with the price of 24.240 USD, and its all-time low was 2.115 USD and was reached on Oct 23, 2023. View more price dynamics on 0A4C chart.
See other stocks reaching their highest and lowest prices.
0A4C stock is 9.30% volatile and has beta coefficient of 3.00. Track ALTIMMUNE INC COM USD0.0001 stock price on the chart and check out the list of the most volatile stocks — is ALTIMMUNE INC COM USD0.0001 there?
Today ALTIMMUNE INC COM USD0.0001 has the market capitalization of ‪545.82 M‬, it has decreased by −0.07% over the last week.
Yes, you can track ALTIMMUNE INC COM USD0.0001 financials in yearly and quarterly reports right on TradingView.
ALTIMMUNE INC COM USD0.0001 is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
0A4C earnings for the last quarter are −0.35 USD per share, whereas the estimation was −0.35 USD resulting in a −0.41% surprise. The estimated earnings for the next quarter are −0.36 USD per share. See more details about ALTIMMUNE INC COM USD0.0001 earnings.
ALTIMMUNE INC COM USD0.0001 revenue for the last quarter amounts to ‪5.00 K‬ USD, despite the estimated figure of 714.00 USD. In the next quarter, revenue is expected to reach 714.00 USD.
0A4C net income for the last quarter is ‪−24.64 M‬ USD, while the quarter before that showed ‪−24.39 M‬ USD of net income which accounts for −1.01% change. Track more ALTIMMUNE INC COM USD0.0001 financial stats to get the full picture.
No, 0A4C doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 59.00 employees. See our rating of the largest employees — is ALTIMMUNE INC COM USD0.0001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALTIMMUNE INC COM USD0.0001 EBITDA is ‪−95.78 M‬ USD, and current EBITDA margin is ‪−19.49 K‬%. See more stats in ALTIMMUNE INC COM USD0.0001 financial statements.
Like other stocks, 0A4C shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALTIMMUNE INC COM USD0.0001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ALTIMMUNE INC COM USD0.0001 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ALTIMMUNE INC COM USD0.0001 stock shows the buy signal. See more of ALTIMMUNE INC COM USD0.0001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.